Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 10/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 10/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 2/20 | 0.37 |
| ▸ | BTK | Q06187 | 2/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23301057 | 1.00 | LPL (0.41) | LPLLIPGACHEJAK2BTK | |
| SCHEMBL15026275 | 0.88 | LPL (0.46) | LPLLIPGJAK2BTKROCK1 | |
| SCHEMBL4674071 | 0.86 | LPL (0.44) | LPLLIPGIRAK4P2RX7 | |
| SCHEMBL29459939 | 0.80 | LPL (0.40) | LPLLIPGJAK2BTKROCK1 | |
| SCHEMBL21458742 | 0.80 | LIPG (0.40) | LPLLIPGJAK2BTKROCK1 | |
| SCHEMBL29897368 | 0.80 | LPL (0.40) | LPLLIPGJAK2BTKROCK1 | |
| SCHEMBL23301083 | 0.80 | LPL (0.40) | LPLLIPGJAK2BTKROCK1 | |
| SCHEMBL20788915 | 0.80 | LPL (0.40) | LPLLIPGJAK2BTKROCK1 | |
| SCHEMBL31483909 | 0.80 | LIPG (0.40) | LPLLIPGJAK2BTKROCK1 | |
| SCHEMBL20536736 | 0.79 | LPL (0.39) | LPLLIPGJAK2BTKP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230009626-A1 | INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | ICHNOS SCIENCES S.A. (CH) | 2023-01-12 | — | — | US | disclosed |
| EP-4051664-A1 | ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS | Cancer Research Technology Limited (GB) | 2022-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230009626-A1 | INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | MAP4K1, MAP4K2, MAP4K4 | LPL 4621/4885LIPG 3806/4885ACHE 3708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.